284 related articles for article (PubMed ID: 34759042)
1. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
[TBL] [Abstract][Full Text] [Related]
2. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
[TBL] [Abstract][Full Text] [Related]
3. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias.
Mettler E; Fottner C; Bakhshandeh N; Trenkler A; Kuchen R; Weber MM
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205773
[TBL] [Abstract][Full Text] [Related]
5. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
[TBL] [Abstract][Full Text] [Related]
7. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
[TBL] [Abstract][Full Text] [Related]
8. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
9. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
10. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.
Cowzer D; Shah RH; Chou JF; Kundra R; Punn S; Fiedler L; DeMore A; Capanu M; Berger MF; Reidy-Lagunes D; Raj N
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38252063
[TBL] [Abstract][Full Text] [Related]
12. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis.
Wei T; Zhang J; Li J; Chen Q; Zhi X; Tao W; Ma J; Yang J; Lou Y; Ma T; Li X; Zhang Q; Chen W; Que R; Gao S; Bai X; Liang T
Mol Oncol; 2020 Sep; 14(9):1966-1977. PubMed ID: 32593194
[TBL] [Abstract][Full Text] [Related]
14. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
[TBL] [Abstract][Full Text] [Related]
15. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
17. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
[TBL] [Abstract][Full Text] [Related]
19. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Gómez A; Trullas R; Roldán FL; Ajami T; Moreno D; Rodríguez-Carunchio L; Alcaraz A; Izquierdo L; Mengual L
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233035
[TBL] [Abstract][Full Text] [Related]
20. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA.
Huebner A; Black JRM; Sarno F; Pazo R; Juez I; Medina L; Garcia-Carbonero R; Guillén C; Feliú J; Alonso C; Arenillas C; Moreno-Cárdenas AB; Verdaguer H; Macarulla T; Hidalgo M; McGranahan N; Toledo RA
Genome Med; 2023 Apr; 15(1):27. PubMed ID: 37081523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
